Clinical Trial Update: EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the radioligand therapy [161Tb]Tb-PSMA-I&T in men with metastatic castration-resistant prostate cancer is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• [161Tb]Tb-PSMA-I&T (PSMA-I&T radioligand labeled with terbium-161)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING